Dr. Eric Verdin

Well, I take a gram most of the time. Now, the obviously what we need is more clinical data in humans and uh a lot of noise has been made about a couple of initial studies that failed and you know and and that's you know that's true peter ti is highly skeptical and and there are you know there are really good reasons to be skeptical about some of the claims that have been made for nmn and nr

Well, I take a gram most of the time. Now, the obviously what we need is more clinical data in humans and uh a lot of noise has been made about a couple of initial studies that failed and you know and and that's you know that's true peter ti is highly skeptical and and there are you know there are really good reasons to be skeptical about some of the claims that have been made for nmn and nr

Well, I take a gram most of the time. Now, the obviously what we need is more clinical data in humans and uh a lot of noise has been made about a couple of initial studies that failed and you know and and that's you know that's true peter ti is highly skeptical and and there are you know there are really good reasons to be skeptical about some of the claims that have been made for nmn and nr

But I think my argument is let's not throw the baby with the bathwater. And there is enough compelling evidence in model systems that NMN and NR actually are having interesting effect to pursue the studies and to conduct the clinical trials. Now, one of the biggest problems I have is

But I think my argument is let's not throw the baby with the bathwater. And there is enough compelling evidence in model systems that NMN and NR actually are having interesting effect to pursue the studies and to conduct the clinical trials. Now, one of the biggest problems I have is

But I think my argument is let's not throw the baby with the bathwater. And there is enough compelling evidence in model systems that NMN and NR actually are having interesting effect to pursue the studies and to conduct the clinical trials. Now, one of the biggest problems I have is

Why is asking the question, and it's something my lab has been working on, why are NAD levels decreasing during aging? And that really has not been studied by many people except us and Eduardo Cini, who was at Mayo Clinic.

Why is asking the question, and it's something my lab has been working on, why are NAD levels decreasing during aging? And that really has not been studied by many people except us and Eduardo Cini, who was at Mayo Clinic.

Why is asking the question, and it's something my lab has been working on, why are NAD levels decreasing during aging? And that really has not been studied by many people except us and Eduardo Cini, who was at Mayo Clinic.

And what we both found is that the reason why NAD levels decrease during aging is because there's another molecule called CD38, which is activated during aging for reasons that are not entirely clear, but in part because of a senescent cell burden. So the CD38 is itself as NAD hydrolase. It chews up NAD.

And what we both found is that the reason why NAD levels decrease during aging is because there's another molecule called CD38, which is activated during aging for reasons that are not entirely clear, but in part because of a senescent cell burden. So the CD38 is itself as NAD hydrolase. It chews up NAD.

And what we both found is that the reason why NAD levels decrease during aging is because there's another molecule called CD38, which is activated during aging for reasons that are not entirely clear, but in part because of a senescent cell burden. So the CD38 is itself as NAD hydrolase. It chews up NAD.

Exactly. So think about your NAD pool like water in a sink. The problem that we're having is a leaky sink. So there's something that's chewing up the NAD. And when you give NMN or NR, you're essentially filling up more water in a leaky sink. Which is not a very satisfying way to solve a problem.

Exactly. So think about your NAD pool like water in a sink. The problem that we're having is a leaky sink. So there's something that's chewing up the NAD. And when you give NMN or NR, you're essentially filling up more water in a leaky sink. Which is not a very satisfying way to solve a problem.

Exactly. So think about your NAD pool like water in a sink. The problem that we're having is a leaky sink. So there's something that's chewing up the NAD. And when you give NMN or NR, you're essentially filling up more water in a leaky sink. Which is not a very satisfying way to solve a problem.

So the way we are going about it, and a growing number of companies are doing this as well, is to actually identify small molecule inhibitors of CD38. And so I have a startup called Napa Therapeutics, which has a large number of these novel molecules. We're testing them.

So the way we are going about it, and a growing number of companies are doing this as well, is to actually identify small molecule inhibitors of CD38. And so I have a startup called Napa Therapeutics, which has a large number of these novel molecules. We're testing them.

So the way we are going about it, and a growing number of companies are doing this as well, is to actually identify small molecule inhibitors of CD38. And so I have a startup called Napa Therapeutics, which has a large number of these novel molecules. We're testing them.

Some of them, some of these inhibitors are not ours, but others have been shown to increase lifespan and to correct some of the aging associated energy deficits. much more sort of efficiently than the precursors.

Some of them, some of these inhibitors are not ours, but others have been shown to increase lifespan and to correct some of the aging associated energy deficits. much more sort of efficiently than the precursors.